Sign In

QOPI
ASCO QOPI

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Sign In

ASCO Connection

Effective May 2021, The Oncology Practice Insider newsletter consolidated with the ASCO Connection newsletter.

ASCO provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high-quality patient care, including updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. The biweekly ASCO Connection newsletter features the latest information on ASCO programs and resources for every member of the oncology community, including information tailored for practice administrators and practice leaders. Subscribe to the ASCO Connection newsletter for Practice News updates.

Date

Questions About the Safe Handling of Hazardous Drugs? ASCO Has Answers.

The American Society of Clinical Oncology (ASCO) released a new frequently asked questions (FAQs) document on the safe handling of hazardous drugs, including those used to treat individuals with cancer, as a resource for its members.

Listen to ASCO Education’s Latest Podcasts on Advanced Practice Providers in Oncology

Learn more about your partners in cancer care. Understand what and who Advanced Practice Providers (APPs) are in your practice, along with the different types of APPs – from advanced practice registered nurses to physicians assistants and how they have been and continue to be an integral part of oncology care and successful oncology care teams across practice settings.  

Enhancing Oncology Model Application Deadline Extended to October 10

The Centers for Medicare & Medicaid Services (CMS) has extended the deadline to apply for the Enhancing Oncology Model (EOM) by 10 days to October 10, 2022 at 11:59 p.m. ET.

New Electronic Health Information Exchange Requirements Begin October 6, 2022

From April 5, 2021, through October 5, 2022, EHI is defined as limited to the EHI identified by the data elements represented in the U.S. Core Data for Interoperability (USCDI). Starting October 6, 2022, the EHI definition is no longer limited to the EHI identified by the data elements represented in the USCDI.

FDA Approves Selpercatinib For Locally Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

On September 21, 2022, the Food and Drug Administration granted regular approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test. Read more. 

FDA Approves Selpercatinib For Locally Advanced or Metastatic RET Fusion-Positive Solid Tumors

On September 21, 2022, the Food and Drug Administration granted accelerated approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. Read more. 

CMS Virtual Listening Session - Gathering Information from Individual Health Care Staff on Emergency Preparedness

Register for an upcoming Virtual Listening Session with health care providers and suppliers on emergency preparedness on Tuesday, September 27 from 1:00 – 2:00 PM ET.

FDA Approves Sodium Thiosulfate to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors

On September 20, 2022, the Food and Drug Administration approved sodium thiosulfate (Pedmark, Fennec Pharmaceuticals Inc.) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month and older with localized, non-metastatic solid tumors. Read more.